Emergent BioSolutions Inc.
EBSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeEmergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States,. At a $470.6M market cap, Emergent BioSolutions Inc. ranks as a small-cap company within healthcare. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Market Cap
$470.6M
Beta
2.33
P/E (TTM)
—
P/E (Fwd)
3.05
EPS (TTM)
$-0.19
EPS (Fwd)
$2.99
ROE
-1.6%
ROA
3.4%
Cash
$160.3M
Total Debt
$584.6M
Free CF
$256.2M
52W Change
44.8%
Annual Financials
Cash vs Debt
Emergent BioSolutions Inc. carries $584.6M in total debt against $160.3M in cash reserves — debt is roughly 3.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $256.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -1.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.4% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $1.64B (2021) to $705.2M (2025), a 57% decline worth watching.
A beta of 2.33 means EBS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. No single metric tells the full story. Reviewing EBS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.